Fagan Associates Inc. increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,138 shares of the biopharmaceutical company’s stock after buying an additional 178 shares during the quarter. Regeneron Pharmaceuticals accounts for about 1.7% of Fagan Associates Inc.’s portfolio, making the stock its 20th largest position. Fagan Associates Inc.’s holdings in Regeneron Pharmaceuticals were worth $6,687,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Joel Isaacson & Co. LLC lifted its holdings in Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Joel Isaacson & Co. LLC now owns 3,253 shares of the biopharmaceutical company’s stock valued at $2,347,000 after purchasing an additional 14 shares in the last quarter. River Street Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 3.0% in the 1st quarter. River Street Advisors LLC now owns 474 shares of the biopharmaceutical company’s stock valued at $389,000 after purchasing an additional 14 shares in the last quarter. Colonial River Wealth Management LLC lifted its holdings in Regeneron Pharmaceuticals by 4.6% in the 4th quarter. Colonial River Wealth Management LLC now owns 341 shares of the biopharmaceutical company’s stock valued at $246,000 after purchasing an additional 15 shares in the last quarter. Mission Wealth Management LP lifted its holdings in Regeneron Pharmaceuticals by 3.6% in the 1st quarter. Mission Wealth Management LP now owns 435 shares of the biopharmaceutical company’s stock valued at $358,000 after purchasing an additional 15 shares in the last quarter. Finally, Crescent Sterling Ltd. lifted its holdings in Regeneron Pharmaceuticals by 3.6% in the 1st quarter. Crescent Sterling Ltd. now owns 459 shares of the biopharmaceutical company’s stock valued at $377,000 after purchasing an additional 16 shares in the last quarter. 89.21% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on REGN. 888 restated a “maintains” rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 5th. Morgan Stanley lifted their price target on Regeneron Pharmaceuticals from $880.00 to $927.00 in a report on Friday, May 5th. Robert W. Baird reduced their price target on Regeneron Pharmaceuticals from $800.00 to $760.00 in a report on Wednesday, June 28th. Truist Financial reduced their price target on Regeneron Pharmaceuticals from $1,050.00 to $1,045.00 in a report on Wednesday, June 28th. Finally, Royal Bank of Canada reduced their price target on Regeneron Pharmaceuticals from $816.00 to $789.00 in a report on Wednesday, June 28th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $868.25.
Insider Activity at Regeneron Pharmaceuticals
In related news, EVP Marion Mccourt sold 250 shares of the company’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $736.00, for a total value of $184,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,553 shares of the company’s stock, valued at $15,127,008. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $716.88, for a total value of $71,688.00. Following the completion of the transaction, the director now directly owns 18,747 shares of the company’s stock, valued at $13,439,349.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Marion Mccourt sold 250 shares of the company’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $736.00, for a total value of $184,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,553 shares of the company’s stock, valued at $15,127,008. The disclosure for this sale can be found here. Insiders sold 700 shares of company stock valued at $506,753 over the last three months. 8.83% of the stock is owned by corporate insiders.
Regeneron Pharmaceuticals Stock Up 0.2 %
Shares of REGN traded up $1.44 during midday trading on Friday, hitting $746.10. The company had a trading volume of 735,295 shares, compared to its average volume of 623,230. The company’s 50-day simple moving average is $738.06 and its 200-day simple moving average is $758.44. The company has a debt-to-equity ratio of 0.11, a quick ratio of 4.67 and a current ratio of 5.45. The firm has a market capitalization of $81.85 billion, a P/E ratio of 20.27, a P/E/G ratio of 2.27 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a 1 year low of $569.65 and a 1 year high of $837.55.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported $8.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.71 by $0.73. The business had revenue of $3.16 billion during the quarter, compared to analysts’ expectations of $2.92 billion. Regeneron Pharmaceuticals had a return on equity of 20.41% and a net margin of 33.81%. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 33.9 EPS for the current year.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Further Reading
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Regeneron Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Regeneron Pharmaceuticals wasn’t on the list.
While Regeneron Pharmaceuticals currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
MarketBeat’s analysts have just released their top five short plays for August 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
